Related Experiment Video

Updated: Jun 19, 2025

Three-Dimensional 3D Tumor Spheroid Invasion Assay
12:19

Three-Dimensional 3D Tumor Spheroid Invasion Assay

Published on: May 1, 2015

57.3K

The Role of the PI3K/Akt/mTOR Axis in Head and Neck Squamous Cell Carcinoma

Qian Jiang1,2, Jingyi Xiao1, Yao-Ching Hsieh2

  • 1Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Nanjing 210093, China.

Biomedicines
|July 27, 2024
PubMed

Insights

Head and neck squamous cell carcinoma (HNSCC) is a common cancer needing new treatments. This review explores targeting the PI3K/AKT/mTOR (PAM) pathway for HNSCC therapy and overcoming drug resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling Pathways

Background:

  • Head and neck squamous cell carcinoma (HNSCC) presents a global health challenge with poor patient outcomes.
  • The PI3K/AKT/mTOR (PAM) signaling pathway is crucial for cell survival and growth, and its dysregulation drives cancer progression.
  • Mutations in PI3K, AKT, and PTEN are common in HNSCC, contributing to treatment resistance.

Purpose of the Study:

  • To review major mutations and dysregulations within the PAM signaling pathway in HNSCC.
  • To evaluate clinical trial outcomes of PAM pathway inhibitors for HNSCC treatment.
  • To examine resistance mechanisms and explore novel therapeutic strategies targeting the PAM pathway in HNSCC.

Main Methods:

  • Literature review of mutations in the PAM pathway in HNSCC.
  • Analysis of clinical trial data for PAM pathway inhibitors.
  • Examination of molecular mechanisms of drug resistance.

Main Results:

  • Significant dysregulations of the PAM pathway are identified in HNSCC.
  • Clinical trials show varying efficacy of PAM pathway inhibitors.
  • Key resistance mechanisms to PAM-targeted drugs are elucidated.

Conclusions:

  • Targeting the PAM pathway is a promising therapeutic strategy for HNSCC.
  • Understanding resistance mechanisms is critical for developing effective combination therapies.
  • Further research is needed to optimize PAM-targeted treatments for HNSCC patients.
Keywords:
HNSCCPAM signaling pathwayinhibitorsresistance

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.5K
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.4K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K